Saved in this browser. Sign in to sync across devices.
What has changed?
On October 9, 2026, Teva announced FDA approval of WELTRUZA (extended-release olanzapine), a monthly injection under the skin for adults with schizophrenia. The pivotal SOLARIS trial demonstrated improvements in schizophrenia symptom and functioning measures. This approval concerns a new delivery formulation of a familiar antipsychotic—it does not show WELTRUZA is superior to all oral or injectable alternatives.
Some people value fewer daily medication tasks, while others prefer pills, different injectables or treatments with different adverse-effect profiles. The person receiving treatment should be central to the decision with their prescriber.
How do options compare?
Daily oral antipsychotics
Schedule: Usually taken every day
Potential advantage: No injection visits; doses can be adjusted under a prescriber's plan.
What to discuss: Remembering doses, physical or metabolic side effects, interactions and whether symptoms are controlled.
Long-acting injectable antipsychotics (LAIs)
Schedule: Given by a clinician on a product-specific schedule
Potential advantage: May help when daily medication is difficult and makes treatment delivery easier to track.
What to discuss: Injection appointments, how a particular product is started, required oral overlap, side effects, and missed-dose planning.
WELTRUZA: monthly olanzapine injection
Schedule: Once-monthly injection under the skin
Potential advantage: FDA approved October 9, 2026 for adult schizophrenia. Its instructions require no loading doses, oral olanzapine supplementation or routine post-injection observation.
What to discuss: Olanzapine-related weight, glucose, lipids and sedation risks still matter; availability and insurance coverage vary.
Not every olanzapine injection follows the same rules. WELTRUZA's approved instructions differ from those of older injectable olanzapine products. A clinician must check the precise formulation; these schedules and monitoring requirements cannot be applied to another product.
What side effects and monitoring matter?
Olanzapine can increase weight, blood sugar and cholesterol; sedation and other adverse effects may also affect daily life. The FDA requires antipsychotics to carry a warning about increased mortality in older adults with dementia-related psychosis. WELTRUZA is not approved for that population.
Post-injection delirium/sedation syndrome (PDSS) has occurred with another injectable olanzapine product; whether it can occur with WELTRUZA is unknown. A new formulation does not remove the need for individualized safety discussion and follow-up.
Questions for the psychiatrist
- How well does the current medicine control symptoms, and which side effects have the greatest impact?
- Would an injectable improve convenience, or create travel, scheduling or cost barriers?
- What side effects and metabolic measurements should be reviewed before and after treatment?
- Are loading doses, oral overlap or observation required for the specific formulation being considered?
- How will the team respond to missed appointments or worsening symptoms?
Related research and practical supports
Some technologies are emerging for negative symptoms, including FDA-cleared prescription software. Other investigational medicines remain under study and may have unresolved risks. These should not be confused with established antipsychotic care.
Sources
- Teva: FDA approval and SOLARIS trial information (October 9, 2026) ↗
- NIMH: Schizophrenia — treatment and support ↗
Checked October 11, 2026. Editorial draft pending independent clinical review; not medical advice. Never start, stop or switch an antipsychotic without your treating clinician.